Distinguishing Hot Versus Cold Fibrosis: Developing Rapid Progressor Signatures to Predict Treatment Response & Optimize Trial Design

• Defining hot & cold fibrosis endotypes using histological features, immune cell infiltration, & molecular signatures
• Developing non-invasive biomarker panels to identify patients in inflammatory versus quiescent fibrotic phases without requiring biopsy
• Tailoring therapeutic approaches & trial inclusion criteria based on disease endotype to maximize treatment effect size

Speakers:

Zoltan Derdak

Medical Director

Takeda Pharmaceutical